Edap Tms S.A. (NASDAQ:EDAP) Short Interest Up 20.6% in March

Edap Tms S.A. (NASDAQ:EDAP) was the recipient of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 56,032 shares, a growth of 20.6% from the March 15th total of 46,459 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average daily volume of 37,347 shares, the days-to-cover ratio is currently 1.5 days.

Wall Street Analyst Weigh In

Several research firms have weighed in on EDAP. Wall Street Zen downgraded shares of Edap Tms from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Edap Tms in a report on Monday, December 29th. Finally, HC Wainwright lowered their price objective on shares of Edap Tms from $14.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, April 9th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Edap Tms has a consensus rating of “Hold” and an average price target of $6.00.

Edap Tms Trading Down 2.8%

Edap Tms stock opened at $3.49 on Friday. The company has a quick ratio of 1.19, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. Edap Tms has a 52 week low of $1.21 and a 52 week high of $5.05. The company has a market capitalization of $130.81 million, a price-to-earnings ratio of -4.53 and a beta of -0.09. The stock has a 50-day moving average price of $4.02 and a 200 day moving average price of $3.26.

Edap Tms (NASDAQ:EDAP) last issued its quarterly earnings results on Wednesday, March 25th. The medical equipment provider reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.09). Edap Tms had a negative return on equity of 100.07% and a negative net margin of 41.24%.The business had revenue of $22.22 million during the quarter, compared to analyst estimates of $21.28 million. Sell-side analysts anticipate that Edap Tms will post -0.6 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Financial Planning Navigators CORP acquired a new position in Edap Tms during the fourth quarter valued at $33,000. Kovack Advisors Inc. acquired a new stake in Edap Tms during the fourth quarter worth about $53,000. Leonteq Securities AG acquired a new position in Edap Tms in the fourth quarter valued at approximately $313,000. Flax Pond Capital LLC acquired a new stake in Edap Tms during the fourth quarter valued at $2,623,000. Finally, Rock Springs Capital Management LP increased its holdings in Edap Tms by 1.3% in the fourth quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the medical equipment provider’s stock valued at $4,233,000 after buying an additional 16,500 shares in the last quarter. Hedge funds and other institutional investors own 62.74% of the company’s stock.

About Edap Tms

Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.